Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Bradley Sumrall (NPI 1679689301)

Field	Value
Entity Type	Individual
Organization	Bradley Sumrall
Address	5430 Bowman Rd
City	Macon
State	GA
ZIP	31210
Taxonomy	Medical Oncology Physician
NPI Enumerated	August 23, 2006

Payer Source	Total Paid
Medicare	$3.1M
Medicaid	$0

Key Findings

This provider’s Medicare business is concentrated in high-cost oncology infusions: J9271, J9144, and J9299 together account for 71.3% of total Medicare revenue, and J9271 alone represents 45.7% of the provider’s Medicare take ($1.4M of $3.1M). The top codes are all infusion/injectable oncology agents (pembrolizumab, daratumumab, nivolumab), indicating the operation is centered on clinic-based biologic/immunotherapy administration rather than solely office evaluation visits.

Medicare is effectively the sole payer on file for this provider: total Medicare revenue is $3.1M and there is no Medicaid billing on file. This makes the practice a single-payer (Medicare-dominant) operation in the dataset, suggesting its patient mix is weighted toward Medicare-eligible populations.

The provider ranks as a major national user of pembrolizumab: J9271 has 32.6K claims, $43 avg paid/claim, $1.4M revenue and ranks #93 of 1841 providers nationally (95th percentile), described as “notably above typical national volume.” By contrast, the other two top revenue drivers J9144 (13.1% of revenue, $403.6K) and J9299 (12.5% of revenue, $383.5K) are at more typical national volumes (69th and 55th percentiles respectively), so the provider’s competitive strength is concentrated on pembrolizumab use.

Beyond the three revenue leaders, the code mix shows a full-service oncology infusion practice with supportive care and diagnostic services. Notable entries include J0897 (denosumab, 5.8% of Medicare revenue, $179.3K, 88th percentile), various lab panels and imaging (80053, 85025, 74177), and supportive/injectable agents (J1439, J0885), indicating onsite administration plus ancillary testing and imaging tied to infusion care.

Evaluation-and-management volumes are unusually high relative to national peers: 99214 accounts for $146.8K and ranks #2900 of 479517 providers (99th percentile; labeled an “extreme outlier”), while 99215 and 99205 also sit at the 98th and 97th percentiles respectively. These elevated E/M ranks suggest the practice couples high infusion throughput with frequent, relatively high-complexity office encounters for established and new patients.

The provider shows adoption of biosimilars alongside originator biologics: Q5107 (bevacizumab biosimilar) produced $86.5K (rank #25 of 78, 69th percentile) and Q5119 (rituximab biosimilar) produced $49.3K (rank #119 of 335, 65th percentile), both described as typical volumes. In contrast, Q5111 (pegfilgrastim biosimilar) is a low-ranked product for this clinician (rank #117 of 123, 4th percentile), indicating selective biosimilar use by product.

The provider has long tenure in Medicare: the NPI was enumerated on 2006-08-23 (~20 years ago), which supports interpretation of these volume patterns as established practice behavior rather than a short-term spike. Combined with concentrated revenue from high-cost immunotherapies, the data portray an experienced, infusion-focused oncology practice with pronounced strength in pembrolizumab administration.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

83 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	32,600	$40	$1.4M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	10,620	$40	$403.6K
J9299	Injection, nivolumab, 1 mg	15,980	$20	$383.5K
J0897	Injection, denosumab, 1 mg	9,960	$20	$179.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,610	$90	$146.8K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	3,760	$20	$86.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	720	$90	$66.5K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	420	$130	$53.9K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	2,240	$20	$49.3K
J1439	Injection, ferric carboxymaltose, 1 mg	39,750	$1	$39.8K

Showing 1–10 of 83

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 83 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Bradley Sumrall — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

83 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	40	15,200	$40	$767.3K
J9299	4	10	15,910	$20	$431.3K
J9144	3	10	9,450	$40	$321.2K
J0897	41	290	2,460	$20	$90.2K
Q5107	2	10	3,280	$20	$69.8K
Q5119	2	10	2,140	$20	$46.8K
J1439	9	30	28,130	$1	$32.3K
Q5111	4	10	270	$110	$28.8K
J0885	8	30	3,970	$10	$26.6K
96413	4	160	170	$90	$20.3K

Showing 1–10 of 83

Related Providers

Other providers that share a Tax Identification Number (TIN) with Bradley Sumrall, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
American Oncology Partners PA	OH	Hematology & Oncology Physician	$0	$11.8M
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0
David Smith	MD	Hematology & Oncology Physician	$6.4M	$0
Stephen Divers	AR	Hematology & Oncology Physician	$3.9M	$1.5K
Robert Muldoon	AR	Hematology & Oncology Physician	$3.2M	$0
Linda Hendricks	GA	Specialist	$3.1M	$0
Sue Tsuda	AR	Medical Oncology Physician	$3.1M	$0

Nearby Providers

Other providers in the same ZIP code as Bradley Sumrall, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Primary Pediatrics, PC	GA	Specialist	$0	$32.9M
Cogent Healthcare Of Georgia PC	GA	Internal Medicine Physician	$0	$4.6M
Harry Moore	GA	Medical Oncology Physician	$2.9M	$0
Tara Adams	GA	Nurse Practitioner	$2.9M	$0
Macon Outpatient Surgery, LLC	GA	Ambulatory Surgical Clinic/Center	$2.2M	$0
Georgia Em-i Medical Services PC	GA	Physician Assistant	$0	$1.9M
Steven Allee	GA	Ophthalmology Physician	$1.7M	$0
Norman Nelson	GA	Ophthalmology Physician	$1.5M	$0
Central Georgia Cancer Care	GA	Specialist	$0	$1.2M
Arpan Bachhawat	GA	Retina Specialist (Ophthalmology) Physician	$1.2M	$0

Bradley Sumrall — Billing Profile & Reimbursement Data

Sign up for Bradley Sumrall — Billing Profile & Reimbursement Data policy alerts

Bradley Sumrall — Billing Profile & Reimbursement Data

Sign up for Bradley Sumrall — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References